Gsk (GSK) Other Non-Current Liabilities (2009 - 2026)
Gsk (GSK) posted quarterly Other Non-Current Liabilities of -$1.5 billion for Q2 2026, down 9.52% year-over-year from -$1.6 billion in Q2 2025, and down 4.21% quarter-over-quarter from -$1.4 billion in Q1 2026.
Gsk (GSK) Other Non-Current Liabilities (2009 - 2026) Analysis & Trends
Gsk's Other Non-Current Liabilities history runs 18 years deep, the most recent figure standing at -$1.5 billion for Q2 2026.
- In Q2 2026, Other Non-Current Liabilities fell 9.52% year-over-year to -$1.5 billion; the TTM figure through Jun 2026 stood at -$1.5 billion (down 9.52% YoY), while the FY2025 annual figure was -$1.3 billion, down 195.93% from the prior year.
- Other Non-Current Liabilities for Q2 2026 stood at -$1.5 billion, down from -$1.4 billion in the prior quarter.
- The five-year high for Other Non-Current Liabilities was $1.4 billion in Q4 2024, with the low at -$1.5 billion in Q2 2026.
- The 5-year median for Other Non-Current Liabilities is -$1.3 billion (2025), against an average of -$795.2 million.
- The sharpest annual moves came in 2022 and 2023: Other Non-Current Liabilities jumped 99.26% in 2022, then plunged 13367.05% in 2023.
- Gsk's Other Non-Current Liabilities stood at $1.1 billion in 2022, then soared by 30.3% to $1.4 billion in 2023, then grew by 2.76% to $1.4 billion in 2024, then plunged by 196.38% to -$1.4 billion in 2025, then decreased by 7.37% to -$1.5 billion in 2026.
- Business Quant data shows GSK's Other Non-Current Liabilities at -$1.5 billion in Q2 2026, -$1.4 billion in Q1 2026, and -$1.4 billion in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Johnson & Johnson | 652.20 Bn | 631.44 Bn | 17.26 Bn |
| 2 | AbbVie | 469.51 Bn | 462.94 Bn | 12.70 Bn |
| 3 | Merck | 376.81 Bn | 369.67 Bn | 12.21 Bn |
| 4 | Novartis Ag | 303.04 Bn | 295.35 Bn | 11.24 Bn |
| 5 | Astrazeneca | 257.61 Bn | 252.71 Bn | 12.86 Bn |
| 6 | Amgen | 237.37 Bn | 223.38 Bn | 7.24 Bn |
| 7 | Gilead Sciences | 181.73 Bn | 178.55 Bn | 6.22 Bn |
| 8 | Pfizer | 159.66 Bn | 147.96 Bn | 10.94 Bn |
| 9 | Gsk | 106.24 Bn | 102.07 Bn | 8.24 Bn |
| 10 | Sanofi | 55.07 Bn | 47.69 Bn | 10.79 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -1.46 Bn |
| Mar 31, 2026 | -1.40 Bn |
| Dec 31, 2025 | -1.36 Bn |
| Sep 30, 2025 | -1.38 Bn |
| Jun 30, 2025 | -1.33 Bn |
| Mar 31, 2025 | -1.30 Bn |
| Dec 31, 2024 | 1.41 Bn |
| Sep 30, 2024 | -1.35 Bn |
| Jun 30, 2024 | -1.42 Bn |
| Mar 31, 2024 | -1.42 Bn |
| Dec 31, 2023 | 1.37 Bn |
| Sep 30, 2023 | -1.35 Bn |
| Jun 30, 2023 | -1.13 Bn |
| Mar 31, 2023 | -1.08 Bn |
| Dec 31, 2022 | 1.05 Bn |
| Sep 30, 2022 | -1.05 Bn |
| Jun 30, 2022 | -1.11 Bn |
| Mar 31, 2022 | -8.05 Mn |
| Dec 31, 2021 | 1.24 Bn |
| Sep 30, 2021 | -1.14 Bn |